Sign in
WithdrawnPhase 1

Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers

Key facts

Who runs it
Ohio State University Comprehensive Cancer Center
Trial code
Status
Withdrawn
Phase
Phase 1
Started
31 Dec 2025
Ended
31 Dec 2025
Type of study
Interventional
Treatments tested
  • Capecitabine
  • Docetaxel
  • Fluorouracil
  • Leucovorin
  • Oxaliplatin
  • Radiation Therapy
  • Surgical Procedure
Record updated
7 February 2025
Why it stopped
PI Decision

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (10)Hide the full registry criteria

Who can take part

  • Patients with histologically proven, cT2N0-T4aN3M0 (TNM 8th edition), gastric or Siewert II-III GEJ adenocarcinoma
  • Evaluation with endoscopic ultrasound (EUS) and staging laparoscopy prior to enrollment is strongly recommended
  • Patient should be a candidate for neoadjuvant chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) or fluorouracil and oxaliplatin (FOLFOX)
  • Patients should be >= 18 years old
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2
  • Patient should be eligible for surgical intervention
  • T1 N0 disease (assessed by endoscopic ultrasound)

Who cannot take part

  • Solitary functioning kidney within the potential radiation field
  • Evidence of distant metastatic disease
  • Peripheral polyneuropathy > National Cancer Institute (NCI) grade II

What happens in this trial

What the trial wants to find out

This phase I trial tests the safety, side effects studies chemotherapy followed by chemotherapy at the same time as radiation therapy (chemoradiation) before surgery (neoadjuvant) in treating patients with stage gastric (stomach) or gastroesophageal junction cancer . Chemotherapy drugs, such as docetaxel, oxaliplatin , leucovorin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy and chemoradiation before surgery may make the tumor smaller and may reduce the amount of normal tissue that needs to be removed.

The group in the trial

  • Treatment (chemotherapy, chemoradiation, surgery)Treatment being tested

    NEOADJUVANT CHEMOTHERAPY: Patients receive FLOT chemotherapy consisting of docetaxel intravenously (IV) , oxaliplatin IV, leucovorin IV, and fluorouracil IV over 24 hours on day 1 or FOLFOX chemotherapy consisting of oxaliplatin IV and leucovorin IV, and fluorouracil IV continuously over 24 hours on days 1 and 2. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity. NEOADJUVANT CHEMORADIATION: Within 4 weeks after completing neoadjuvant chemotherapy, patients undergo radiation therapy in 25 fractions over 5 weeks. Patients also receive either fluorouracil IV continuously for 24 hours on days 1-5 or capecitabine orally (PO) twice daily (BID) on days 1-5. Cycles repeat weekly for 5 weeks in the absence of disease progression or unacceptable toxicity. SURGERY: Within 4-8 weeks after neoadjuvant chemoradiation, patients undergo surgical resection according to tumor location and per surgeon expertise.

    Treatment: Capecitabine, Docetaxel, Fluorouracil, Leucovorin, Oxaliplatin, Radiation Therapy, and Surgical Procedure

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Total Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction (GEJ) and Gastric Cancers: A Pilot Trial
Record updated
7 February 2025